The short version of unapproved substance fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-25. Anything still debated is marked as such rather than presented as settled.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
The 5th SFG was assigned responsibility for two sectors of western Iraq-the western and southern JSOAs (Joint Special Operations Areas-also known as Ops Boxes), one element termed FOB 51 (Operating Base 51) and commanded by AOB 520 and AOB 530, was composed of ODAs from 1st Battalion 5th SFG, they were stationed out of H-5 Air Base and were responsible for western Iraq. 2nd and 3rd Battalions deployed from Ali Al Salem Air Base as FOB 52 and 53 and were assigned to southern Iraq; attached to all teams were Special Tactics airmen from the 23rd Special Tactics Squadron to guide in close air support and manage the airspace above the ODA teams. A company element from the 19th SFG was attached to TF Dagger as were several regular and National Guard infantry companies to provide FOB security and to act as a QRF. As the prospect of war grew A company, 1st Battalion, 19th SFG, were tasked with liaison roles supporting conventional forces: ODA 911 and ODA 913 were to support the I MEF; ODA 914 was divided into two elements, one supporting the 3rd Infantry Division with ODA 916 and the other supporting British Forces; ODA 915 was attached to the 101st Airborne Division; and ODA 912 was tasked with providing PSD for General Harrell, the commander of CFSOCC (Combined Forces Special Operations Component Command). Responsibility for special operations in northern Iraq was assigned to CJSOTF-North (Combined Joint Special Operations Task Force-North/Task Force Viking) was formed around the 10th SFG, working alongside them would 3rd Battalion 3rd SFG.
=== Alternatives === There is strong evidence that chlorhexidine and alcohol used to clean skin prior to surgery is better than any formulation of povidone-iodine. While the 2016 World Health Organization guidelines recommended alcohol-based CHG Chlorhexidine for surgical skin preparation based on low-to-moderate quality evidence, subsequent clinical data has clarified this comparison. A large-scale 2024 non-inferiority trial involving over 3,300 patients undergoing cardiac or abdominal surgeries found that alcohol-based povidone-iodine is non-inferior to alcohol-based CHG Chlorhexidine in preventing surgical site infections (SSIs).
=== Pharmacodynamics === Nicotinic acid activates the HCA2 receptor, which has effects in addition to lowering serum cholesterol and triglyceride concentrations: antioxidative, anti-inflammatory, antithrombotic, improved endothelial function and plaque stability, all of which counter development and progression of atherosclerosis. Nicotinic acid inhibits cytochrome P450 enzymes CYP2E1, CYP2D6 and CYP3A4. Niacin produces a rise in serum unconjugated bilirubin in normal individuals and in those with Gilbert's Syndrome. However, in the Gilbert's Syndrome, the rise in bilirubin is higher and clearance is delayed longer than in normal people. One test used to aid in diagnosing Gilbert's Syndrome involves intravenous administration of nicotinic acid (niacin) in a dose of 50 mg over a period of 30 seconds.
Sources: en.wikipedia.org
Military forces in several countries, including France, the United States, and the United Kingdom, have used modafinil as an alternative to amphetamines for managing fatigue during combat operations and extended missions. The US Air Force approved modafinil for specific missions as a fatigue countermeasure. Modafinil is also available to astronauts aboard the International Space Station for fatigue management.
Phosphorus(III) chloride (PCl3) and phosphorus(V) chloride (PCl5) will also convert carboxylic acids to acid chlorides, by a similar mechanism. One equivalent of PCl3 can react with three equivalents of acid, producing one equivalent of H3PO3, or phosphorus acid, in addition to the desired acid chloride. PCl5 reacts with carboxylic acids in a 1:1 ratio, and produces phosphorus(V) oxychloride (POCl3) and hydrogen chloride (HCl) as byproducts.
HETP = a measure of the resolving power of the column [m] A = Eddy-diffusion parameter, related to channeling through a non-ideal packing [m] B = diffusion coefficient of the eluting particles in the longitudinal direction, resulting in dispersion [m2 s−1] C = Resistance to mass transfer coefficient of the analyte between mobile and stationary phase [s] u = speed [m s−1] In open tubular capillaries, the A term will be zero as the lack of packing means channeling does not occur. In packed columns, however, multiple distinct routes ("channels") exist through the column packing, which results in band spreading. In the latter case, A will not be zero. The version of the Van Deemter equation that applies to capillary columns called the Golay equation which is as follows:
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.